Get to know our clinical trials
Phase 3 clinical trial to evaluate the efficacy and safety of maintenance treatment with sacituzumab tirumotecan versus standard treatment in recurrent platinum-sensitive ovarian cancer.
THE PRIMARY OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF SACITUZUMAB TIRUMOTECAN IN MAINTENANCE THERAPY WITH BEVACIZUMAB.
Technical Summary
- PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE TREATMENT WITH SACITUZUMAB TIRUMOTECAN WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD TREATMENT AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
- Code EudraCT: 2023-508015-23
- Protocol number: MK-2870-022
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: Sacituzumab tirumotecán
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.